252 related articles for article (PubMed ID: 19232037)
21. The 12-month safety profile of dexlansoprazole, a proton pump inhibitor with a dual delayed release formulation, in patients with gastro-oesophageal reflux disease.
Dabholkar AH; Han C; Paris MM; Perez MC; Atkinson SN; Peura DA
Aliment Pharmacol Ther; 2011 Feb; 33(3):366-77. PubMed ID: 21118280
[TBL] [Abstract][Full Text] [Related]
22. Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis.
Metz DC; Howden CW; Perez MC; Larsen L; O'Neil J; Atkinson SN
Aliment Pharmacol Ther; 2009 Apr; 29(7):742-54. PubMed ID: 19210298
[TBL] [Abstract][Full Text] [Related]
23. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease.
Fass R; Chey WD; Zakko SF; Andhivarothai N; Palmer RN; Perez MC; Atkinson SN
Aliment Pharmacol Ther; 2009 Jun; 29(12):1261-72. PubMed ID: 19392864
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the efficiency of two different proton pump inhibitor formula in treatment of patients with atypical gastroesophageal reflux disease: a prospective randomized study.
Lin XH; Luo JC; Ting PH; Chang TE; Huang YH; Hou MC; Lee FY
J Gastroenterol Hepatol; 2020 Dec; 35(12):2096-2102. PubMed ID: 32401385
[TBL] [Abstract][Full Text] [Related]
25. Dexlansoprazole, a modified release formulation of an enantiomer of lansoprazole, for the treatment of reflux esophagitis.
Fock KM; Ang TL
Curr Opin Investig Drugs; 2008 Oct; 9(10):1108-15. PubMed ID: 18821474
[TBL] [Abstract][Full Text] [Related]
26. Dexlansoprazole: A proton pump inhibitor with a dual delayed-release system.
Emerson CR; Marzella N
Clin Ther; 2010 Aug; 32(9):1578-96. PubMed ID: 20974316
[TBL] [Abstract][Full Text] [Related]
27. Delayed release dexlansoprazole in the treatment of GERD and erosive esophagitis.
Wittbrodt ET; Baum C; Peura DA
Clin Exp Gastroenterol; 2009; 2():117-28. PubMed ID: 21694835
[TBL] [Abstract][Full Text] [Related]
28. Withdrawing PPI therapy after healing esophagitis does not worsen symptoms or cause persistent hypergastrinemia: analysis of dexlansoprazole MR clinical trial data.
Metz DC; Pilmer BL; Han C; Perez MC
Am J Gastroenterol; 2011 Nov; 106(11):1953-60. PubMed ID: 21844923
[TBL] [Abstract][Full Text] [Related]
29. Control of 24-hour intragastric acidity with morning dosing of immediate-release and delayed-release proton pump inhibitors in patients with GERD.
Howden CW; Ballard ED; Koch FK; Gautille TC; Bagin RG
J Clin Gastroenterol; 2009 Apr; 43(4):323-6. PubMed ID: 18758373
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics and pharmacodynamics of an orally disintegrating tablet formulation of dexlansoprazole.
Kukulka M; Nudurupati S; Perez MC
Therap Adv Gastroenterol; 2016 Nov; 9(6):759-769. PubMed ID: 27803731
[TBL] [Abstract][Full Text] [Related]
31. Safety and pharmacodynamics of lansoprazole in patients with gastroesophageal reflux disease aged <1 year.
Springer M; Atkinson S; North J; Raanan M
Paediatr Drugs; 2008; 10(4):255-63. PubMed ID: 18590344
[TBL] [Abstract][Full Text] [Related]
32. Maintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release.
Fass R; Inadomi J; Han C; Mody R; O'Neil J; Perez MC
Clin Gastroenterol Hepatol; 2012 Mar; 10(3):247-53. PubMed ID: 22155561
[TBL] [Abstract][Full Text] [Related]
33. Absorption, distribution, metabolism and excretion of [14C]dexlansoprazole in healthy male subjects.
Grabowski B; Lee RD
Clin Drug Investig; 2012 May; 32(5):319-32. PubMed ID: 22455762
[TBL] [Abstract][Full Text] [Related]
34. Indirect comparison of randomised controlled trials: comparative efficacy of dexlansoprazole vs. esomeprazole in the treatment of gastro-oesophageal reflux disease.
Wu MS; Tan SC; Xiong T
Aliment Pharmacol Ther; 2013 Jul; 38(2):190-201. PubMed ID: 23718547
[TBL] [Abstract][Full Text] [Related]
35. Bioavailability, safety, and pharmacodynamics of delayed-release dexlansoprazole administered as two 30 mg orally disintegrating tablets or one 60 mg capsule.
Kukulka M; Nudurupati S; Perez MC
Therap Adv Gastroenterol; 2016 Nov; 9(6):770-780. PubMed ID: 27803732
[TBL] [Abstract][Full Text] [Related]
36. Safety, pharmacokinetics, and pharmacodynamics of S-(-)-pantoprazole sodium injections after single and multiple intravenous doses in healthy Chinese subjects.
Jiao HW; Sun LN; Li YQ; Yu L; Zhang HW; Wang MF; Yu LY; Yuan ZQ; Xie LJ; Chen J; Meng L; Zhang XH; Wang YQ
Eur J Clin Pharmacol; 2018 Mar; 74(3):257-265. PubMed ID: 29167917
[TBL] [Abstract][Full Text] [Related]
37. Treatment of gastroesophageal reflux disease: two new oral formulations dexlansoprazole MR and esomezol (esomeprazole strontium).
Parekh PJ; Oldfield EC; Johnson DA
Expert Opin Pharmacother; 2014 Jun; 15(9):1215-22. PubMed ID: 24749891
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics and pharmacodynamics of lansoprazole in children 13 to 24 months old with gastroesophageal reflux disease.
Heyman MB; Zhang W; Huang B; Chiu YL; Amer F; Winter HS
J Pediatr Gastroenterol Nutr; 2007 Jan; 44(1):35-40. PubMed ID: 17204950
[TBL] [Abstract][Full Text] [Related]
39. Dose-response relationship of lansoprazole to gastric acid antisecretory effects.
Blum RA; Hunt RH; Kidd SL; Shi H; Jennings DE; Greski-Rose PA
Aliment Pharmacol Ther; 1998 Apr; 12(4):321-7. PubMed ID: 9690720
[TBL] [Abstract][Full Text] [Related]
40. Age-dependent pharmacokinetics of lansoprazole in neonates and infants.
Zhang W; Kukulka M; Witt G; Sutkowski-Markmann D; North J; Atkinson S
Paediatr Drugs; 2008; 10(4):265-74. PubMed ID: 18590345
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]